Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder

Abstract

ImportanceSuicidal behavior is a significant clinical concern in individuals with borderline personality disorder (BPD), but the effectiveness of pharmacotherapy on reducing suicide risk has remained unknown.ObjectiveTo study the comparative effectiveness of different pharmacotherapies in preventing attempted or completed suicides in patients with BPD in Sweden.Design, Setting and ParticipantsIn this comparative effectiveness research study, nationwide Swedish register databases of inpatient care, specialized outpatient care, sickness absences, and disability pensions were used to identify patients aged 16 to 65 years with registered treatment contact due to BPD during 2006 to 2021. Data were analyzed from September to December 2022. A within-individual design was used, in which each patient was used as their own control to eliminate selection bias. To control protopathic bias, sensitivity analyses were conducted, in which the first 1 or 2 months of medication exposure were omitted from the analyses.Main outcomes and MeasuresHazard ratio (HR) for attempted or completed suicide.ResultsA total of 22 601 patients with BPD (3540 [15.7%] men; mean [SD] age, 29.2 [9.9] years) were included. During the 16-year follow-up (mean [SD] follow-up, 6.9 [5.1] years), 8513 hospitalizations due to attempted suicide and 316 completed suicides were observed. Attention-deficit/hyperactive disorder (ADHD) medication treatment, compared with its nonuse, was associated with a decrease in the risk of attempted or completed suicide (HR, 0.83; 95% CI, 0.73-0.95; false discovery rate [FDR]–corrected P = .001). Treatment with mood stabilizers did not have a statistically significant association with the main outcome (HR, 0.97; 95% CI, 0.87-1.08; FDR-corrected P = .99). Antidepressant (HR, 1.38; 95% CI, 1.25-1.53; FDR-corrected P < .001) and antipsychotic (HR, 1.18; 95% CI, 1.07-1.30; FDR-corrected P < .001) treatments were associated with an elevated risk of attempted or completed suicide. Of the investigated pharmacotherapies, treatment with benzodiazepines was associated with the highest risk of attempted or completed suicide (HR, 1.61; 95% CI, 1.45-1.78; FDR-corrected P < .001). These results remained similar when controlling for potential protopathic bias.Conclusions and RelevanceIn this comparative effectiveness research study of a Swedish nationwide cohort, ADHD medication was the only pharmacological treatment associated with reduced risk of suicidal behavior among patients with BPD. Conversely, the findings suggest that benzodiazepines should be used with care among patients with BPD due to their association with increased risk of suicide.

Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes

“…There were some differences in the results when stratified by age, which can be at least partially related to statistical power issues, mainly caused by less frequent use of amphetamine among adolescents and young adults. Our results showed consistently that lisdexamphetamine was associated with decreased risk of psychiatric hospitalization and suicidal behavior, which is well in line with the results from studies concerning individuals with borderline personality disorder, as well as individuals with amphetamine use disorder …”

Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

“…APA guidelines recommend those particularly in treatment of cognitive-perceptual BPD symptoms, whereas The National Institute for Health and Care Excellence (NICE) guidelines state that antipsychotics can be considered only as a crisis treatment, prescribed for no longer than 1 week ( 54 ). A recently published comparative effectiveness research study, indicated that among all pharmacotherapies employed in BPD patients, only the treatment with attention deficit hyperactivity disorder medication was associated with a reduced risk of suicidal behaviors ( 55 ). Some authors suggest that therapy of BPD needs to be prioritized when BPD and depression co-occur ( 1 ).…”

Suicidality and nonsuicidal self-injury in females diagnosed with attention-deficit hyperactivity disorder - a narrative review

“…Prada et al found that treatment with methylphenidate in a group consisting of mostly females with ADHD-BPD comorbidity was associated with improvement in response to dialectical behavior therapy (DBT) with regard to Trait-State Anger scores, motor impulsiveness, depression severity and ADHD severity, when compared with no pharmacological treatment [37]. Recent evidence suggests that in a group of BPD patients, consisting mainly of females (84.3%), the only medication group that statistically significantly reduced the risk of suicide attempt and completed suicide was ADHD medication (including: methylphenidate, lisdexamphetamine, atomoxetine, dexamphetamine and polytherapy) [38 ▪▪ ].…”